ERBB2 and breast carcinoma: One-fourth of HER2-overexpressing breast tumors eventually develop resistance to trastuzumab, which is a monoclonal anti-HER2 antibody, and endocrine therapy alone is not sufficient for some high-risk hormone-receptor-positive breast cancers.